Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review
International Journal of Molecular Sciences · 15.04.2023 · 24 (8) · 7329
DOI: 10.3390/ijms24087329 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.04.2023. Verfasst von Ching-Ya Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan. Hauptthemen laut MEDLINE: Pharmacogenetics, Psoriasis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taiwan, Chang Gung Memorial Hospital, CGMH-XMCG Joint Research Program.
Abstract (Originalsprache)
The efficacy and the safety of psoriasis medications have been proved in trials, but unideal responses and side effects are noted in clinical practice. Genetic predisposition is known to contribute to the pathogenesis of psoriasis. Hence, pharmacogenomics gives the hint of predictive treatment response individually. This review highlights the current pharmacogenetic and pharmacogenomic studies of medical therapy in psoriasis. HLA-Cw*06 status remains the most promising predictive treatment response in certain drugs. Numerous genetic variants (such as ABC transporter, DNMT3b, MTHFR, ANKLE1, IL-12B, IL-23R, MALT1, CDKAL1, IL17RA, IL1B, LY96, TLR2, etc.) are also found to be associated with treatment response for methotrexate, cyclosporin, acitretin, anti-TNF, anti-IL-12/23, anti-IL-17, anti-PDE4 agents, and topical therapy. Due to the high throughput sequencing technologies and the dramatic increase in sequencing cost, pharmacogenomic tests prior to treatment by whole exome sequencing or whole genome sequencing may be applied in clinical in the future. Further investigations are necessary to manifest potential genetic markers for psoriasis treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
- Cancer Vaccine & Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.
- Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan.
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen 361028, China.
- Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.
ORCID-Profile: Ching-Ya Wang, Chuang-Wei Wang, Chun-Bing Chen, Wei-Ti Chen, Ya-Ching Chang
Förderung
- National Science and Technology Council, Taiwan
- Chang Gung Memorial Hospital
- CGMH-XMCG Joint Research Program
Zitieren
APA
Wang, C. Y., Wang, C. W., Chen, C. B., Chen, W. T., Chang, Y. C., Hui, R. C., & Chung, W. H. (2023). Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review. International Journal of Molecular Sciences, 24(8), 7329. https://doi.org/10.3390/ijms24087329
Vancouver
Wang CY, Wang CW, Chen CB, Chen WT, Chang YC, Hui RC, et al. Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review. International Journal of Molecular Sciences. 2023;24(8):7329. doi:10.3390/ijms24087329
BibTeX
@article{Wang2023,
author = {Wang, Ching-Ya and Wang, Chuang-Wei and Chen, Chun-Bing and Chen, Wei-Ti and Chang, Ya-Ching and Hui, Rosaline Chung-Yee and Chung, Wen-Hung},
title = {Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {8},
pages = {7329},
doi = {10.3390/ijms24087329}
}
EUVIMED